Short-Term Intervention with Liraglutide Improved Eating Behavior in Obese Women with Polycystic Ovary Syndrome
Abstract
AIM: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) stimulate satiety leading to reductions in food intake and body weight. The effects of long- acting GLP-1 RA liraglutide on eating behavior of women with PCOS have not been investigated yet. METHODS: Thirty-six obese women with PCOS (mean ± SD, aged 31.2 ± 7.8 years, with BMI 38.7 ± 0.1 kg/m(2)), pretreated with metformin (1000 mg BID) were switched to liraglutide 1.2 mg QD sc for 12 weeks. Adiposity parameters and eating behavior as assessed by Three-Factor Eating Questionnaire (TFEQ-R18) were examined at baseline and after 12 weeks. RESULTS: Subjects treated with liraglutide lost on average 3.8 ± 0.1 kg (p < 0.001). Significant reductions of waist circumference and visceral adipose tissue (VAT) mass, volume and area were demonstrated from liraglutide induction to the end of the study. TFEQ-R18 scores were significantly different pre- and post-liraglutide intervention. After treatment with liraglutide the uncontrolled eating (UE) score decreased from 36.8 ± 24.5 to 19.6 ± 18.4 (p < 0.001) and emotional eating (EE) score decreased from 49.9 ± 33.3 to 28.5 ± 26.9 (p < 0.001). Scores for cognitive restraint (CR) were not changed. CONCLUSIONS: Short-term liraglutide treatment was associated with weight loss and significantly improved eating behavior in obese women with PCOS.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Weight loss through lifestyle modification, medications, or bariatric surgery improves insulin resistance, reduces hyperandrogenism, and alleviates PCOS clinical severity.
“Consistently, weight loss through lifestyle modification (comprising dietary modification, physical activity and/or behavioural change), medications (metformin, orlistat, incretin mimetics) orbariatric surgery improves insulin resistance, reduces hyperandrogenism and alleviates PCOS clinical severity (Moran et al. , 2011; Vosnakis et al. , 2013; Jensterle et al. , 2015).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Jensterle et al., 2015
In a study of 36 women pre-treated with metformin, after 12 weeks, liraglutide decreased the uncontrolled eating score and emotional eating score, which additionally influenced body weight loss (3.8 ± 0.1 kg).
“The study concerning the impact of liraglutide on eating behavior was performed on a group of 36 women pre-treated with metformin. After 12 weeks, it turned out that liraglutide decreased the uncontrolled eating score and emotional eating score, which additionally influenced body weight loss (3.8 ± 0.1 kg) [96].”
From The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome (2022) · cites this paper as [96]
The citation lists haven’t been fetched yet
References 37 · Cited by 86
- Authors
- Jensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M., & Janez, A.
- Affiliations
- Ljubljana University Medical Centre (SI)
- Corresponding author
- Jensterle, Mojca
- Venue
- Endocrine Research
- Publisher
- Informa UK Limited
- Published
- 2014-10-20
- Volume
- 40
- Issue
- 3
- Pages
- 133-138
- ISSN
- 0743-5800 (ISSN-L)
- 1532-4206
- OpenAlex
- W1968073470
- Cited by
- 86
- References
- 37
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 5 · 2023: 10 · 2022: 6 · 2021: 9 · 2020: 5 · 2019: 6 · 2018: 6 · 2017: 8 · 2016: 3 · 2015: 10
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, polycystic ovary syndrome, obesity, dietary habits, GLP-1 receptor agonists, weight loss, visceral adipose tissue, emotional eating, uncontrolled eating, cognitive restraint, metformin, satiety
- MeSH terms
- Liraglutide, Adult, Blood Glucose, Body Weight, Feeding Behavior, Female, Humans, Hypoglycemic Agents, Insulin, Obesity, Polycystic Ovary Syndrome, Body Mass Index, Intra-Abdominal Fat, Waist Circumference, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
